

including monitoring, distribution, and reviewing our security programs for scheduled products.

In addition to Federal regulation, 42 States, including New York, California, Pennsylvania, Illinois, and Florida, have adopted the Uniform Controlled Substances Act, which contains controls similar to the Federal act.

EFFECT OF CONTROLS ON PRESCRIPTION EXPERIENCE: 1971 COMPARED TO 1975

Since the passage of the Controlled Substances Act of 1970, there has been a marked change in the prescription experience for anorectic products.

These changes may be summarized as follows:¹

	1971	1975
1. Total patient visits for obesity.....	23,668,000	20,601,000
2. Prescription usage:		
Medical prescriptions of anorectics (initial).....	18,373,000	12,413,000
Total 2d or subsequent prescriptions.....	7,707,000	7,213,000
Total anorectic prescriptions.....	26,080,000	19,626,000
3. Total anorectic prescriptions:		
(1) Amphetamines.....	16,232,000	5,504,000
(Initial prescriptions).....	(13,201,000)	(2,745,000)
(2) Nonamphetamines.....	9,848,000	14,122,000
(Initial prescriptions).....	(5,172,000)	(9,668,000)
Total anorectic prescriptions.....	26,080,000	19,626,000
4. Reduction in total anorectic prescriptions from 1971 to 1975.....		-6,454,000

These figures demonstrate that the Controlled Substances Act has accomplished a dramatic reduction in the prescription of amphetamine anorectic products, but that a continuing medical requirement for those products remains.

The figures also demonstrate that while there has been an overall reduction in the total prescriptions of anorectic products, there also remains a very sizable patient population, consisting of millions of Americans, among the 30 to 40 million obese, who are receiving medically supervised treatment for their condition.

PENNWALT'S MANUFACTURE, DISTRIBUTION, AND SALES

All of the Federal regulations I described previously are complied with by Pennwalt in its manufacture, distribution, and sales. In addition, at the plant, production and shipping are monitored closely by management to assure the absence of loss and the detection of any attempted theft. As noted earlier, detailed records and monthly and quarterly reports to the DEA show each transaction both intraplant and to customers, its size and the identity of the customer.

At the present time, Pennwalt sells its prescription products, including Biphedamine and Ionamin, only to nonprofit hospitals and to approximately 450 wholesale distributors.

These wholesalers handle the complete line of Pennwalt products and all of them are also registered and regulated in their handling of scheduled drugs by the Drug Enforcement Administration. In addi-

¹ These data are based upon the National Disease and Therapeutic Drug Index (Non-Endocrine Obesity) and its National Prescription Audit.